Fig. 2
BM-MSCs-pCas9/gIL10 transplantation induces increased expression of IL-10 in diabetic mice with myocardial infarction. a Schematic depicts the experiment protocol. BM-MSCs were isolated and cultured, and then transfected with pCas9/dgCtrl or pCas9/dgIL10. Mice models of diabetic MI were established via coronary artery ligation. STZ-induced diabetic mice were injected with BM-MSCs-pCas9/dgCtrl, pCas9/dgIL10 or BM-MSCs pCas9/dgIL10 at 2 sites near the border zone of infarction (medial and lateral zones) 1 h post myocardial infarction (MI) accomplishment, and 7 days later the mice were subjected to examination. b In vivo optical bioluminescence imaging (BLI). Luciferase gene was inserted into plasmids, and BLI was detected using the Xenogen In Vivo Imaging System 1-weeks post transplantation by intravenously injecting luciferase substrate. Four groups were treated as follows: Control (PBS only), BM-MSCs-pCas9/gCtrl (BM-MSCS transfected with control CRISPR/Cas9 plasmids), pCas9/gIL10 (direct injection of CRISPR/Cas9 plasmids express IL-10), and BM-MSCs-pCas9/gIL10 (BM-MSCS transfected with control CRISPR/Cas9 plasmids express IL10). The number of cells was 2*106, and the mass of pCas9/dgIL10 was 40 pmol. c The IL10 expressions in peri-infarct area in the control MI heart or hearts treated with BM-MSCs pCas9/gCtrl, pCas9/gIL10 or BM-MSCs pCas9/gIL10 were detected using Western blotting 1-week post transplantation. β-actin was used as a loading control. d The production of IL-10 in in peri-infarct area was examined by ELIAS 1-week post transplantation. Data represent means ± SD. ***p < 0.001, n = 8